Physician profile

Michael D Mcnamara

Psychiatry · Manchester, NH

NPI 1861477259

$754,106.92

in general payments reported to CMS, 2019-2025

22 companies · $256K in 2025

The $256K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$367,520.20
Consulting Fee$63,631.25
Travel and Lodging$56,200.61
Food and Beverage$21,804.14
Honoraria$21,725.00
Education$27.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $217,773.92 2019-2025 Rexulti, Abilify Maintena, Abilify Asimtufii
Neurocrine Biosciences, INC. $149,895.11 2019-2025 Ingrezza
E.R. Squibb & Sons, L.L.C. $100,136.36 2024-2025 Cobenfy
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $81,420.22 2021-2025 Caplyta
Alkermes, INC. $69,000.85 2021-2025 Lybalvi, Vivitrol, Aristada
Teva Pharmaceuticals USA, INC. $49,247.20 2019-2025 Uzedy, Austedo, Austedo Xr
Abbvie INC. $34,482.90 2021-2025
Axsome Therapeutics, INC. $24,253.85 2023-2025 Auvelity
Janssen Pharmaceuticals, INC $15,424.38 2019-2025 Invega Sustenna, Invega Trinza, Spravato
Allergan, INC. $7,977.62 2019-2020
Vanda Pharmaceuticals INC. $1,664.97 2019-2025 Fanapt, Hetlioz
Indivior INC. $1,281.40 2019-2023 Perseris
Otsuka Pharmaceutical Development & Commercialization, INC. $653.08 2019-2025 Rexulti, Abilify Maintena
Sage Therapeutics, LLC $284.83 2021-2023
Sunovion Pharmaceuticals INC. $190.57 2019-2020
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Avanir Pharmaceuticals, INC. $124.99 2019
Novo Nordisk INC $124.23 2025 Wegovy
Janssen Scientific Affairs, LLC $61.18 2025 Invega Sustenna
Amgen INC. $41.06 2019
Luye Pharma (USA) Ltd. $31.38 2025 Erzofri Extended-Release
Sanofi-Aventis U.S. LLC $22.79 2024
Lundbeck LLC $14.03 2023 Rexulti

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael D Mcnamara

$754,106.92

in general payments reported 2019-2025

Years
2019-2025
Top company
Otsuka America Pharmaceutical, INC.
Context
The $256K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).

https://glasscript.com/doctor/416427/michael-d-mcnamara

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.